Cannabis Europa London 2026 reveals programme as European market confronts its most consequential year
Cannabis Europa London 2026, taking place on 26–27 May at The Barbican, has published its full programme for what is set to be the most consequential edition of the event to date.
The two-day conference brings together more than 1,750 investors, operators, policymakers, and healthcare professionals to examine the structural shifts defining the European cannabis market in 2026 — from US federal rescheduling and UK policy stagnation, to price compression, telehealth restrictions, and the question of whether long-term investment in cannabis is finally turning a corner.
The 2026 programme spans two stages — the Main Stage and the Greenhouse Stage — and features more than 50 speakers from across Europe, North America, and beyond.
The View from the White House
In December 2025, President Trump signed an executive order directing federal agencies to move ahead with loosening cannabis regulations, returning the issue to the centre of US political debate. A dedicated session at Cannabis Europa London will examine what is actually happening at the federal level and what it means for European stakeholders.
Saphira Galoob, CEO of the US Cannabis Roundtable, will be joined by Bryan Lanza, former Communications Director for President Trump’s Transition Team, for a direct discussion on the state of rescheduling — how much depends on the White House, how much sits with the DEA and the courts, and what continued federal uncertainty signals for transatlantic investors and operators.
Deal Flow and M&A in European Cannabis
As Europe’s legal medical market approaches €1.5 billion in value, institutional capital is beginning to re-engage — but on its own terms. The “Deal Flow & Due Diligence” session will examine where the money is moving and what acquiring companies are actually looking for.Raj Grover, CEO of High Tide — which has pursued an active European acquisition strategy — will be joined by Ivan Kapustin, Managing Partner of AMA Invest, for a panel examining which markets represent credible M&A targets, how valuations are evolving, and what governance and financial reporting standards institutional investors now expect before they commit.
A separate session, ‘Is Cannabis as an Investment Opportunity Turning a Corner?’, will feature Karan Wadhera, Managing Partner of Casa Verde Capital, examining the risk/return picture after two difficult years for cannabis capital markets and whether the underlying fundamentals now justify renewed conviction.
Europe’s Telehealth Crossroads
Telemedicine fuelled much of Europe’s medical cannabis growth — and it is now under pressure. Regulators in Germany and elsewhere are moving to restrict online prescribing and mail-order sales, following Poland’s more restrictive approach.
‘The End of E-Prescriptions? Europe’s Telehealth Crossroads’ will feature Kristine Lütke, former Member of the German Bundestag and Senior Health Advisor at 365 Sherpas GmbH, and Dirk Heitepriem, President of the German Cannabis Business Association (BvCW). The session will examine compliance strategies, EU cross-border prescription rules, and the broader implications for operators, clinics, and patients who have come to rely on online access.
Women’s Health and Cannabis
One of the most underfunded and underserved areas in both cannabis research and mainstream healthcare, women’s health will take centre stage on Day Two.
‘Can Cannabis Help to Close the Gender Health Gap?’ brings together Nabila Chaudhri, Medical Director at Montu UK; Dr Grace Blest-Hopley, Founder and Chief Science Officer at Hystelica; and Dr Suzanne Mulvehill, Founder of the Female Orgasm Research Institute and the Women’s Cannabis Project. The panel will examine the clinical evidence, the barriers women face in accessing medical cannabis, the lack of product innovation serving women’s specific needs, and what needs to change across regulation, research, and industry practice.
Price Compression and Supply Chain Resilience
Germany’s bulk cannabis prices have collapsed under supply pressure, while EU-GMP products still command a premium — a divergence that is reshaping operator economicsacross the continent. ‘Navigating Europe’s Price Compression’ will feature Deepak Anand of ASDA Consultancy and Barry Laxer, Founder and CEO of Cielo Verde, in a panel assessing margin management strategies, the case for consolidation, and whether supply-chain rationalisation can restore commercial balance.
UK Policy: From Caution to Action?
Nearly eight years after medical cannabis was rescheduled in the UK, NHS access remains limited while private clinics continue to grow. A dedicated UK State of Play session will ask whether the country can move from its current cautious stance to a more coherent and open cannabis framework — and what that would require of policymakers.
A further session, ‘Policy In Practice: From Workplace Testing to Driving’, will examine how UK law applies to patients in day-to-day life. Richard List, National Secretary of the Association of Police Controlled Drug Liaison Officers (APCDLO), Robert Jappie, Partner at Fieldfisher, and Sal Aziz, Director of PatientsCann, will address the gap between legal principle and operational practice across roadside enforcement and workplace policy.
Mike Morgan-Giles, CEO of the Cannabis Industry Council and Adam Windish, CEO of BRITISH CANNABIS will also introduce the CIC’s newly developed Travelling with Medical Cannabis Guide. Designed to support patients, healthcare providers, and industry stakeholders, the guide outlines the key considerations, risks, and practical steps required to travel safely and legally with medical cannabis.
About Cannabis Europa London 2026
Cannabis Europa London 2026 takes place on 26–27 May at The Barbican, London. The event features two stages — the Main Stage and the Greenhouse Stage — across two full days.
General Release delegate passes are available at £444 until 1 May 2026. VIP Passes, which include an exclusive networking dinner on the evening of 26 May, VIP lounge access throughout both days, priority seating, a dedicated concierge, and fast-track registration, are available at £757. BoC Awards Party tickets are available at £50.
Registration and the full programme are available at cannabis-europa.com/events/cannabis-europa-london-2026/
